Trifluridine adverse reactions

Revision as of 22:25, 2 January 2014 by Gerald Chi (talk | contribs) (→‎Adverse Reactions)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Trifluridine
VIROPTIC® FDA Package Insert
Description
Clinical Pharmacology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Adverse Reactions

The most frequent adverse reactions reported during controlled clinical trials were mild, transient burning or stinging upon instillation (4.6%) and palpebral edema (2.8%). Other adverse reactions in decreasing order of reported frequency were superficial punctate keratopathy, epithelial keratopathy, hypersensitivity reaction, stromal edema, irritation, keratitis sicca, hyperemia, and increased intraocular pressure.[1]

References

  1. "http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022211s000_sumr.pdf" (PDF). External link in |title= (help)

Adapted from the FDA Package Insert.